Dupont Capital Management Corp Aldeyra Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$5.08 - $7.09 $169,839 - $237,039	-33,433 Reduced 12.67%	230,491 $0
Q3 2022 Oct 31, 2022	BUY	$3.8 - $7.74 $402,393 - $819,611	105,893 Added 67.01%	263,924 $1.41 Million
Q1 2022 Apr 27, 2022	SELL	$3.25 - $5.17 $13,334 - $21,212	-4,103 Reduced 2.53%	158,031 $702,000
Q4 2021 Jan 31, 2022	BUY	$3.5 - $9.63 $344,218 - $947,091	98,348 Added 154.18%	162,134 $649,000
Q3 2021 Nov 03, 2021	BUY	$7.94 - $11.31 $506,460 - $721,419	63,786 New	63,786 $560,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.